|
TEVA SETTLES PATENT DISPUTE WITH BMS OVER GENERIC PARAPLATIN
Teva Pharmaceutical and Bristol-Myers Squibb (BMS) have settled a patent infringement lawsuit over BMS’ cancer drug Paraplatin (carboplatin) in a deal that could give Teva a jump on the generic competition. This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives